• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home StudyGraphics

#VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals

byConstance Wu
April 14, 2021
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals
Share on FacebookShare on TwitterShare on LinkedIn

1. Prior infection with SARS-CoV-2 in the first wave (i.e. before June 2020) was linked to significant protection against reinfection in the second wave in the general population.

2. Protection from repeat SARS-CoV-2 infection was relatively weaker in older populations.

Evidence Rating Level: 2 (Good)

Study Rundown: Little is known about the protective immunity from SARS-CoV-2 repeat infections after an initial positive infection. In this population-level observational study, PCR testing records of those infected with SARS-CoV-2 during the first surge were tracked through to the second surge in Denmark. Infection rates during the second surge were compared among individuals with positive and negative PCR tests during the first surge. Analyses found that those who tested positive during the first surge were significantly less likely to have tested positive during the second surge compared to those who tested negative during the first surge. This protective effect was observed weakly in older populations where the likelihood of testing positive upon previous infection was notably higher compared to younger cohorts. There were no observed differences between sexes or the time between first infection and reinfection. This study is strengthened by its large subject pool and natural setting; this inclines the study to apply to practical public health settings. Limitations include the observational nature where one must assume similar characteristics (e.g., health behaviors, the likelihood of acquiring or seeking testing, exposure risk) among between groups and within groups over time; in other words, this study suggested but did not prove that prior infection directly prevented reinfection.

Click to read the study in The Lancet

Relevant Reading: What we know about covid-19 reinfection so far

RELATED REPORTS

Ensitrelvir associated with reduced risk of Covid-19 among household contacts

Worsening kidney function observed following SARS-CoV-2 infection in children

In-Depth [retrospective cohort]: This study utilized a national surveillance dataset to access the SARS-CoV-2 PCR testing records of all those tested in Denmark between February 26th and December 21st, 2020. Only those tested during both the first and second surges were included in further analysis. The first surge was considered to be the period before June 2020, while the second surge was between Sept 1, 2020-Dec 31, 2020. Adjusted rate ratios with 95% CI intervals were derived from a Poisson regression as adjusted for sex, age group. The positivity rates were 2.20% (11 727 of 533 381) and 4.32% (150 159 of ~3 480 000) for the first and second surges, respectively. During the second surge, daily rates of infection were 5.35 positive tests per 100 000 people for those who previously tested positive in the first surge compared to 27.06 positive tests per 100 000 people for those who tested negative in the first surge. The adjusted relative risk of infection in the second surge was 0.195 (95% CI 0.155 – 0.246) when comparing those with a prior positive test to those with a negative test during the first surge. The overall protective effect against repeat infection was determined to be 78.8% (95% CI 74.9–82.1). The sub-analysis of those above the ages of 65 indicated a protective effect of only 47.1% (24.7–62.8) whereas all other younger cohorts reached levels above 80% (p <0.0001).

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: reinfectionSARS-CoV-2
Previous Post

Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe acute kidney injury 

Next Post

#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Infectious Disease

Ensitrelvir associated with reduced risk of Covid-19 among household contacts

May 26, 2026
Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
Next Post
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH

#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Post-COVID Syndrome is linked to higher mortality risk and multi-organ dysfunction

#VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals

#VisualAbstract: Post-COVID syndrome associated with significant morbidity and mortality beyond respiratory illnesses

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
  • Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status
  • Children with autism spectrum disorder may have reduced fecal microbial diversity
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.